RPH 203

Drug Profile

RPH 203

Alternative Names: RPH-203

Latest Information Update: 05 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator R-Pharm
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bone cancer; Osteoporosis

Most Recent Events

  • 31 May 2013 Preclinical trials in Bone cancer in Australia (Parenteral)
  • 31 May 2013 Preclinical trials in Osteoporosis in Australia (Parenteral)
  • 31 May 2013 R-Pharm plans a phase I trial for Bone cancer and osteoporosis (in volunteers) in Australia (ACTRN12613000651785)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top